Direct-to-consumer virtual care company Hims & Hers has acquired at-home lab testing facility Sigmund NJ LLC, also known as Trybe Labs.

Hims & Hers said the acquisition of the New Jersey-based testing facility will allow customers to take better control of their health and permit providers to access a range of data and biomarkers that may help identify risk of disease before it develops.

In addition to providing compounded GLP-1 medications, the company's telehealth platform connects consumers to licensed healthcare professionals.

Hims & Hers also offers a range of prescription and non-prescription health and wellness products as well as over-the-counter drug and device products; cosmetics; and supplement products that focus on general wellness, sexual health and wellness, skincare and hair care. 

In addition, the company offers medical consultation and post-consultation support services and health and wellness products via wholesale partners.

The addition of a testing facility will allow Hims & Hers to support at-home blood draws and more complete whole body testing. 

Moreover, according to the company, the acquisition will widen its ability to offer a range of personalized treatments, supplements and medications, as well as accelerate its expansion into clinical categories, such as low testosterone, perimenopausal and menopausal support.

The at-home testing capability is expected to be available over the next year.

"The healthcare that customers expect and deserve today is on-demand care with treatments designed specifically for them," Dr. Patrick Carroll, chief medical officer of Hims & Hers, said in a statement. 

"This next generation of healthcare is what we're building at Hims & Hers by providing the best information and set of options to each customer that comes to our platform so they can access precisely the care that is best for them," Carroll said. "Access to richer data allows us to deepen the insights that providers can use on our platform to guide their clinical decisions for each individual patient."

Carroll added, "At-home lab testing is one more exciting step towards elevating the personal, comprehensive care customers in this country should expect."

THE LARGER TREND

Earlier this month, Hims & Hers received backlash over its 60-second commercial dubbed "Sick of the System" that ran during the Super Bowl on Fox. 

The commercial stated that "obesity is America's deadliest epidemic" and claims that "something is broken, and it's not our bodies; it's the system." It then says the $160 billion weight loss industry "feeds on our failure." 

It goes on to say there are medications that work that are "priced for profits," and the system "wasn't built to help us" but to "keep us sick and stuck." 

The commercial then presents Hims & Hers as a solution, stating that the company "offers life-changing weight loss medications that are affordable and doctor-trusted."

The FDA has released concerns over unapproved versions of GLP-1 drugs, including compounded semaglutides, as an option for weight loss.

Prior to the ad airing during the Super Bowl, Senators Dick Durbin, D-Ill., and Roger Marshall, R-Kan., sent a letter to the FDA's acting Commissioner Dr. Sarah Brenner expressing concerns that the ad risks misleading patients by promoting a specific type of weight loss medication while omitting safety or side effect information.  

Shortly after the Super Bowl ad aired, Hims & Hers stock [NYSE: HIMS] soared by more than 24%. 

The company's stock surged again today amidst news of the acquisition and is currently trading at around $71.40 per share on the New York Stock Exchange, the highest the stock has traded since the company went public through a SPAC in 2021. 

Hims & Hers is expected to release its fourth quarter and full year 2024 earnings on Monday.